About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
AMRN - Amarin Corporation p...| Previous Close | $4.54 | Open | |
| Volume | 500 | Market Cap | 1.796B |
| Yield | Last Dividend |
| Why Amarin Stock May Rise From Here | 06/22/21 |
| No summary available. | |
| 4 Biotech Stocks to Watch: AMRN AVXL RGB... | 06/22/21 |
| U.S. biotech stocks are off to a strong start this week. It didnt take long for investors to get over the Feds forecast for interest rate hikes by 202... | |
| Why Amarin Fell Again Today | 06/22/21 |
| Another Vascepa generic is launched in the U.S. | |
| Amarin: outperform | 06/22/21 |
| Minneapolis (www.aktiencheck.de) - Rating-Update: Carl Byrnes, Analyst von Northland Capital Markets, stuft die Aktie von Amarin Corporation plc (ISIN... | |
| Amarin''s Vascepa patent defense ends in... | 06/21/21 |
| Amarin''s Vascepa patent defense ends in a loss at the Supreme Court esagonowsky Mon, 06/21/2021 - 10:47 | |
| Amarin''s Vascepa patent defense ends in... | 06/21/21 |
| For a drug company with one commercial product, losing a patent challenge right on the heels of a major new FDA approval is a serious setback. Thats w... | |
| Amarin falls; unfavorable court ruling a... | 06/21/21 |
| No summary available. | |
| U.S. Supreme Court denies Amarins bid to... | 06/21/21 |
| WASHINGTON The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal ba... | |
| U.S. Supreme Court denies Amarins bid to... | 06/21/21 |
| The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC (AMRN.O) subsidiary to revive patents on its heart drug Vascepa in a legal battl... | |
| U.S. Supreme Court denies Amarin''s bid ... | 06/21/21 |
| The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC (AMRN.O) subsidiary to revive patents on its heart drug Vascepa in a legal battl... | |
| Amarin Corporation (AMRN) Presents At Go... | 06/10/21 |
| No summary available. | |
| Amarin Corporation (AMRN) Presents At Je... | 06/10/21 |
| No summary available. | |
| Traders shouldnt Staggering on this: Ama... | 06/08/21 |
| Amarin Corporation plc (AMRN) with the stream of 1.89% also noticed, India Stellantis N.V. (STLA) encountered a rapid change of 0.35% in the last hour... | |
| Amarin Corporation plc (AMRN) CEO John T... | 06/08/21 |
| No summary available. | |
| Further Insights into Mechanism of Actio... | 06/02/21 |
| (MENAFN - GlobeNewsWire - Nasdaq)main-body-container" itemprop="articleBody"> DUBLIN, Ireland and BRIDGEWATER, N.J., June 02, 2021 (GLOBE NEWSWIRE) --... | |
| Amarin Corporation''s (AMRN) CEO John Th... | 06/02/21 |
| No summary available. | |
| The UKs first drug approval via Project ... | 05/24/21 |
| In early May, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved a targeted anticancer drug, AstraZeneca''s Tagrisso (osimerti... | |
| CinCor Pharma Announces Appointments of ... | 05/19/21 |
| Experienced biopharmaceutical executive, John F. Thero, Chief Executive Officer of Amarin Corporation PLC, a commercial-stage cardiovascular company S... | |
| Why Amarin Trounced the Market on Tuesda... | 05/18/21 |
| Investors reacted positively to a company presentation at an industry convention. | |
| In the clinic for May 18, 2021 | 05/18/21 |
| Clinical updates, including trial initiations, enrollment status and data readouts and publications: Amarin, Apnimed, Bergenbio, Catalyst, Cybin, GSK,... | |
| Amarin to Present at Two Investor Confer... | 05/17/21 |
| Amarin Corporation plc announced that John F. Thero, Amarin''s president and chief executive officer, and Karim Mikhail, Amarins senior vice president... | |
| Amarin Highlights Multiple Scientific Fi... | 05/17/21 |
| REDUCE-IT ?? patients experienced substantial cardiovascular (CV) risk reduction with icosapent ethyl regardless of the presence or degree of dyslipid... | |
| Amarin Highlights Multiple Scientific Fi... | 05/17/21 |
| REDUCE-IT ?? patients experienced substantial cardiovascular (CV) risk reduction with icosapent ethyl regardless of the presence or degree of dyslipid... | |
| REDUCE-IT?? Heart Failure Analyses by VA... | 05/15/21 |
| Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new h... | |
| REDUCE-IT Heart Failure Analyses by VASC... | 05/15/21 |
| Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new h... | |
| Why Amarin Stock Is Tumbling Today | 05/12/21 |
| An analyst downgraded the drugmaker. | |
| Amarin (NASDAQ:AMRN) Lowered to Sell at ... | 05/12/21 |
| Amarin (NASDAQ:AMRN) was downgraded by The Goldman Sachs Group from a neutral rating to a sell rating in a research note issued to investors on Wednes... | |
| Date | 2021-04-29 (BMO) | Est. (EPS/Rev.) | ($0.05)/ 147.1M |
| Actual (EPS/Rev.) | / $142.17 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| FEAT. ANDRE 3000 | JOHN KROLIKOWSKI JR | 84.00 % | Follow |
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
| Options Eagle | George | 76.00 % | Follow |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Option short-term trading [Unusual] | Debashis K | 66.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
